{
    "2018-11-02": [
        [
            {
                "time": "2018-11-15",
                "original_text": "Novartis abandons effort for U.S. approval of biosimilar rituximab",
                "features": {
                    "keywords": [
                        "Novartis",
                        "abandons",
                        "U.S.",
                        "approval",
                        "biosimilar",
                        "rituximab"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology",
                "features": {
                    "keywords": [
                        "Novartis",
                        "ASH",
                        "SABCS",
                        "pipeline",
                        "portfolio",
                        "hematology",
                        "oncology"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-26",
                "original_text": "AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Q3",
                        "Earnings",
                        "Beat",
                        "Estimates",
                        "EPS",
                        "View",
                        "Up"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-08",
                "original_text": "Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates",
                "features": {
                    "keywords": [
                        "Conatus",
                        "Q3",
                        "Loss",
                        "In",
                        "Line",
                        "Revenues",
                        "Lag",
                        "Estimates"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-08",
                "original_text": "Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates",
                "features": {
                    "keywords": [
                        "Conatus",
                        "Q3",
                        "Loss",
                        "In",
                        "Line",
                        "Revenues",
                        "Lag",
                        "Estimates"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-20",
                "original_text": "A Look at Merck’s Diabetes and Women’s Health Business",
                "features": {
                    "keywords": [
                        "Merck",
                        "Diabetes",
                        "Women’s",
                        "Health",
                        "Business"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}